Macroautophagy/autophagy promotes resistance to KRAS G12D -targeted therapy through glutathione synthesis

Leng Han,Lingjun Meng,Jiao Liu,Yangchun Xie,Rui Kang,Daniel J. Klionsky,Daolin Tang,Yuanyuan Jia,Enyong Dai

DOI: https://doi.org/10.1016/j.canlet.2024.217258

IF: 9.756

2024-09-15

Cancer Letters

Abstract:KRAS G12D mutation-driven pancreatic ductal adenocarcinoma (PDAC) represents a major challenge in medicine due to late diagnosis and treatment resistance. Here, we report that macroautophagy (hereafter autophagy), a cellular degradation and recycling process, contributes to acquired resistance against novel KRAS G12D -targeted therapy. The KRAS G12D protein inhibitor MRTX1133 induces autophagy in KRAS G12D -mutated PDAC cells by blocking MTOR activity, and increased autophagic flux prevents apoptosis. Mechanistically, autophagy facilitates the generation of glutamic acid, cysteine, and glycine for glutathione synthesis. Increased glutathione levels reduce reactive oxygen species production, which impedes CYCS translocation from mitochondria to the cytosol, ultimately preventing the formation of the APAF1 apoptosome. Consequently, genetic interventions (utilizing ATG5 or BECN1 knockout) or pharmacological inhibition of autophagy (with chloroquine, bafilomycin A 1 , or spautin-1) enhance the anticancer activity of MRTX1133 in vitro and in various animal models (subcutaneous, patient-derived xenograft, and orthotopic). Moreover, the release of histones by apoptotic cells triggers an adaptive immune response when combining an autophagy inhibitor with MRTX1133 in immunocompetent mice. These findings establish a new strategy to overcome KRAS G12D -targeted therapy resistance by inhibiting autophagy-dependent glutathione synthesis.

oncology